Literature DB >> 19708862

Association between lipoprotein subfraction profile and the response to hepatitis C treatment in Japanese patients with genotype 1b.

H Mawatari1, M Yoneda, K Fujita, Y Nozaki, Y Shinohara, H Sasaki, H Iida, H Takahashi, M Inamori, Y Abe, N Kobayashi, K Kubota, H Kirikoshi, A Nakajima, S Saito.   

Abstract

Pegylated interferon and ribavirin combination therapy is the standard treatment for patients with chronic hepatitis C (CHC). Some groups have reported a relation between lipid values and response while others have reported that microsomal triglyceride transfer protein, a key enzyme in the assembly and secretion of lipoproteins, was related to hepatitis C virus (HCV). The aim of this study was to investigate the association between the lipoprotein profiles, classified according to size, and hepatitis C treatment and the usefulness for predicting the outcome of treatment. Forty-four patients with CHC (27 men and 17 women) were included in the study. The serum cholesterol and triglyceride (TG) levels in the lipoprotein subclasses were determined using high-performance liquid chromatography with gel permeation columns, which classified lipoproteins into 20 subfractions based on particle size. According to a univariate analysis, those who achieved an sustained viral response (SVR) had a significantly higher serum total cholesterol level, higher cholesterol levels in the low-density lipoprotein subfraction (25.5 nm in diameter) and the very low-density lipoprotein (VLDL) subfraction (44.5 and 36.8 nm), and a higher serum TG level in the VLDL subfraction (44.5 nm), compared with the corresponding values in the non-SVR group. Higher serum cholesterol and TG concentrations in the lipoprotein subfractions were predictive of an SVR to therapy for HCV infection with genotype 1b prior to the start of interferon treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19708862     DOI: 10.1111/j.1365-2893.2009.01179.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  4 in total

1.  Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

Authors:  Josephine H Li; Xiang Qian Lao; Hans L Tillmann; Jennifer Rowell; Keyur Patel; Alexander Thompson; Sunil Suchindran; Andrew J Muir; John R Guyton; Stephen D Gardner; John G McHutchison; Jeanette J McCarthy
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

2.  The impact of host factors on management of hepatitis C virus.

Authors:  Mahmoud Aboelneen Khattab; Mohammed Eslam
Journal:  Hepat Mon       Date:  2012-04-30       Impact factor: 0.660

3.  Serum lipoprotein profiles and response to pegylated interferon plus ribavirin combination therapy in patients with chronic HCV genotype 1b infection.

Authors:  Yoshio Aizawa; Noritomo Shimada; Hiroshi Abe; Nobuyoshi Seki; Yuta Aida; Haruya Ishiguro; Makiko Ika; Keizo Kato; Akihito Tsubota
Journal:  Hepat Mon       Date:  2013-05-27       Impact factor: 0.660

4.  Impact of Chronic Hepatitis C Virus Genotype 1b Infection on Triglyceride Concentration in Serum Lipoprotein Fractions.

Authors:  Tomohisa Nagano; Nobuyoshi Seki; Yoichi Tomita; Tomonori Sugita; Yuta Aida; Munenori Itagaki; Satoshi Sutoh; Hiroshi Abe; Akihito Tsubota; Yoshio Aizawa
Journal:  Int J Mol Sci       Date:  2015-08-31       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.